Columvi (glofitamab-gxbm) — Medica
Diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma arising from follicular lymphoma
Initial criteria
- age ≥ 18 years
- has received two or more lines of systemic therapy
- medication is given as a single agent
- has or will receive pretreatment with Gazyva (obinutuzumab intravenous infusion) before the first dose of Columvi
- prescribed by or in consultation with an oncologist
Approval duration
1 year